Gee Ho Park

Gee Ho Park

Auto-generated profile, based on publicly available information

Gee Ho Park

GeneOne Life Science Inc, Seoul, Korea

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in Science Robotics
Verified
Journal Article
Closed access
PDF file
BSBeomjune Shin
Beomjune Shin
JHJonghyun Ha
Jonghyun Ha
MLMinhee Lee
Minhee Lee
KPKeunhwan Park
Keunhwan Park
GPGee Ho Park
Gee Ho Park
HKHo-Young Kim
Ho-Young Kim
A hygroresponsive actuation system crawls on a moist surface using aligned nanofibers that quickly swell and shrink.

8 April 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
BJByoungjun Jeon
Byoungjun Jeon
BJBoseong Jeong
Boseong Jeong
SJSeunghoon Jee
Seunghoon Jee
YHYan Huang
Yan Huang
YKYoungmin Kim
Youngmin Kim
TCTae Hyun Choi
Tae Hyun Choi
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

7 September 2016 in mBio
Verified
Journal Article
Open access
PDF file
SRSandeep Steven Reddy
Sandeep Steven Reddy
HFHui-Chen Chang Foreman
Hui-Chen Chang Foreman
TSThubten Ozula Sioux
Thubten Ozula Sioux
GPGee Ho Park
Gee Ho Park
VPValeria Poli
Valeria Poli
LKLaurie T. Krug
Laurie T. Krug
A challenging property of gammaherpesviruses is their ability to establish lifelong persistence. The establishment of latency in B cells is thought to involve active virus engagement of host signaling pathways. Pathogenic effects of these viruses during latency or following reactivation can be devastating to the host. Many cancers, including those associated with members of the gammaherpesvirus family, Kaposi’s sarcoma-associated herpesvirus and Epstein-Barr virus, express elevated levels of active host signal transducer and activator of transcription-3 (STAT3). STAT3 is activated by tyrosine phosphorylation in response to many cytokines and can orchestrate effector responses that include proliferation, inflammation, metastasis, and developmental programming. However, the contribution of STAT3 to gammaherpesvirus pathogenesis remains to be completely understood. This is the first study to have identified STAT3 as a critical host determinant of the ability of gammaherpesvirus to establish long-term latency in an animal model of disease. Following an acute infection, murine gammaherpesvirus 68 (MHV68) established latency in resident B cells, but establishment of latency was dramatically reduced in animals with a B cell-specific STAT3 deletion. The lack of STAT3 in B cells did not impair germinal center responses for immunoglobulin (Ig) class switching in the spleen and did not reduce either total or virus-specific IgG titers. Although ablation of STAT3 in B cells did not have a global effect on these assays of B cell function, it had long-term consequences for the viral load of the host, since virus latency was reduced at 6 to 8 weeks postinfection. Our findings establish host STAT3 as a mediator of gammaherpesvirus persistence.IMPORTANCEThe insidious ability of gammaherpesviruses to establish latent infections can have detrimental consequences for the host. Identification of host factors that promote viral latency is essential for understanding latency mechanisms and for therapeutic interventions. We provide the first evidence that STAT3 expression is needed for murine gammaherpesvirus 68 to establish latency in primary B cells during an active immune response to infection. STAT3 deletion in B cells does not impair adaptive immune control of the virus, but loss of STAT3 in B cells has a long-lasting impact on viral persistence. These results indicate a potential therapeutic benefit of STAT3 inhibitors for combating gammaherpesvirus latency and, thereby, associated pathologies.

16 July 2022 in Translational Medicine Communications
Verified
Journal Article
Open access
PDF file
SKSagar B Kudchodkar
Sagar B Kudchodkar
Paolo FagonePaolo Fagone
Paolo Fagone
OKOmkar U Kawalekar
Omkar U Kawalekar
MJMoonsup Jeong
Moonsup Jeong
CRChristine C. Roberts
Christine C. Roberts
KMKar Muthumani
Kar Muthumani
In the present study, the effect(s) of the immunomodulatory drug GLS-1027 on various cell types involved in inflammation were investigated. GLS-1027 reduced LPS-stimulated secretion of pro-inflammatory cytokines by macrophage or monocytic cells and cell lines. This reduction was likely due in part to decreased activation of NF-κB family transcription factors and inhibition of p38 MAPK signaling in GLS-1027-treated cells. Independent from its effects on macrophages, GLS-1027 inhibited dendritic cell maturation and differentiation of naïve CD4+ T cells into Th17 cells, reducing the production of typical pro-inflammatory cytokines associated with both processes. In vivo administration of GLS-1027 prevented the development of type 1 diabetes in NOD mice which correlated with reduced serum levels of IL17A in GLS-1027 treated animals and reduced ex vivo production of IL17A from both spleen and lymph-node cells. Overall, our data show that GLS-1027 can reduce inflammation through multiple actions, including the reduction of pro-inflammatory cytokine production by innate immune cells, the inhibition of dendritic cells maturation, and the inhibition of Th17 cells polarization.